As a medical oncologist and Chief of Memorial Sloan Kettering’s Lymphoma Service, I work with my clinical and basic-science colleagues to accelerate the translation of recent scientific discoveries into novel treatment strategies to improve the cure rate and survival of patients with Hodgkin and non-Hodgkin lymphoma.
I joined Memorial Sloan Kettering in 2013 with two decades of experience in treating and managing people with lymphoma, and with an extensive background in translational scientific research. I am particularly interested in developing novel targeted therapies and linking them to biomarkers (early markers) that can help match patients with the most effective and minimally toxic medicines.
I have served as the principal investigator of more than 60 clinical trials in patients with Hodgkin and non-Hodgkin lymphoma, including national and international multi-center studies. I have led the efforts of developing the first FDA-approved targeted drug for the treatment of Hodgkin lymphoma in more than three decades (Brentuximab vedotin).
Nationally, I have led a National Cancer Institute-funded Specialized Programs of Research Excellence (SPOREs) in lymphoma focused on developing novel treatment strategies for Hodgkin and non-Hodgkin lymphoma. I also serve on the Scientific Advisory Board of the Lymphoma Research Foundation, and am a member of the National Cancer Institute Lymphoma Steering Committee.
- Clinical Expertise: Hodgkin and Non-Hodgkin Lymphomas; New Targeted Therapies
- Languages Spoken: English
- Education: MD, The University of Damascus School of Medicine (Damascus, Syria)
- Residencies: Medical College of Ohio (Toledo, Ohio); SUNY Downstate Medical Center (Brooklyn, NY)
- Fellowships: Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by Anas Younes
- A Phase 1/2a Study of Ibrutinib plus Nivolumab in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
- A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
- A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
- A Phase I Study of JNJ-64052781 in Patients with Recurrent or Persistent B-Cell Cancers
- A Phase II Study of Nivolumab in Patients with Classical Hodgkin Lymphoma that Has Returned After Autologous Stem Cell Transplantation
- A Phase III Study of Ibrutinib (PCI-32765) plus R-CHOP Chemotherapy in Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical Trials Co-Investigated by Anas Younes
- A Phase I Study of MT-3724 for the Treatment of Relapsed B-cell Non-Hodgkin Lymphoma
- A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
- A Phase I/II Study of IMO-8400 in Patients with Persistent or Recurrent Waldenstrom's Macroglobulinemia
- A Phase IB Study of MPDL3280A plus Obinutuzumab in Patients with Recurrent or Persistent Lymphoma
- A Phase II Study of IPI-145 in Patients with Persistent Slow-Growing Non-Hodgkin Lymphoma
- A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
- A Phase III Study of Rituximab plus Ibrutinib or Placebo in Patients with Persistent Waldenstrom's Macroglobulinemia